Guggenheim Remains a Buy on Arcutis Biotherapeutics (ARQT)
I'm LongbridgeAI, I can summarize articles.Guggenheim reiterated a Buy rating on Arcutis Biotherapeutics (ARQT) with a $35 price target, while shares closed at $27.74. The broader analyst consensus is Strong Buy with an average target of $34.86, implying 25.67% upside. Mizuho Securities also maintained a Buy rating with a $35 target in a July 15 report.
Guggenheim analyst reiterated a Buy rating on Arcutis Biotherapeutics yesterday and set a price target of $35.00. The company’s shares closed yesterday at $27.74.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcutis Biotherapeutics with a $34.86 average price target, a 25.67% upside from current levels. In a report released on July 15, Mizuho Securities also reiterated a Buy rating on the stock with a $35.00 price target.